Higbie V, LaPelusa MB, Shah P, Childress M, Gasco A, An A, Bent AH, Kee BK, Kopetz S , Le P, Morris VK, Pant S, Parseghian C, Shen JP, Wolff RA, Overman MJ
The active ingredients involved (semaglutide, tirzepatide) have published clinical-trial results in their FDA-approved forms, detailed above
GLP-1 agonists are promising for MASH treatment because they target multiple aspects of the disease, including fat accumulation, inflammation, and insulin resistance, which are all key factors in MASH progression
Overweight individuals are those with a body mass index (BMI) greater than or equal to 25, while obesity is defined as a BMI of 30 or higher [4]
P-21 What It Is: A small molecule mimetic of ciliary neurotrophic factor (CNTF) designed for neurogenesis and neuroprotection
GUO: Marta, from the Brookings Institution, she has been watching this battle between the drug companies that invented these products and everyone else trying to get in on the action